EUVIMEDEUVIMED entdecken
Crossref

CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis

Xin Song, Chensheng Jiang, Mengli Yu, Chao Lu, Xinjue He iD

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Xin Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Colitis, Disease Models, Animal, Receptors, CCR2, Fibrosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Zhejiang Provincial Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Cenicriviroc (CVC) is a CCR2/CCR5 antagonist that has been shown to be effective in the treatment of inflammatory and fibrotic diseases. Our study evaluated its efficacy in colitis.

Methods

Mouse models of DSS‐induced acute and chronic colitis were established. The efficacy of CVC in colitis was assessed by disease activity index (DAI) scores, histological assessment of inflammation and fibrosis, and expression assays of key molecules. In in vitro experiments, HT29 cell line was exposed to TNFα to study inflammatory signaling in intestinal epithelial cells. CCD‐18Co colonic myofibroblasts and human primary colonic fibroblasts were activated by TGFβ1 to mimic fibroblast activation.

Results

In HT29 cells, CVC significantly reduced mRNA expression of CCL5 ( P < 0.01) but had no effect on CCL2. Furthermore, CVC reduced downstream CX3CL1 ( P < 0.01) and TNFα ( P < 0.05) expression, thereby inhibiting inflammatory progression. In acute colitis mice, CVC significantly reduced DAI scores and serum TNFα levels ( P < 0.05) and attenuated colonic inflammation as shown by HE staining. Meanwhile, CVC had no adverse effects on the liver, heart, and kidney of mice. On the other hand, in cellular models of chronic colitis, CVC decreased the expression of fibrosis markers, including FN, CTGF, α‐SMA, and MMP9, and inhibited TGFβ1‐induced fibrotic activation ( P < 0.01). In addition, CVC attenuated colonic fibrosis in chronic colitis mice. Moreover, CVC significantly promoted autophagy, which contributed to its regulation of inflammation.

Conclusions

CVC significantly inhibited inflammation through CCL5/CCR5 signaling without damaging vital organs and suppressed fibrotic activation in chronic colitis, suggesting its great potential to relieve colonic inflammation and fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisDisease Models, AnimalReceptors, CCR2FibrosisCCR5 Receptor AntagonistsColonAnimalsHumansReceptors, CCR5HT29 CellsTumor Necrosis Factor-alphaMiceMaleChemokine CCL5Mice, Inbred C57BLChronic DiseaseDextran SulfateImidazolesSulfoxides

Stichwörter der Autor:innen

CCR2CCR5cenicriviroccolitis

Substanzen

cenicrivirocReceptors, CCR2CCR5 Receptor AntagonistsReceptors, CCR5Tumor Necrosis Factor-alphaCcr2 protein, mouseChemokine CCL5CCR5 protein, mouseDextran SulfateImidazoles

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Gastroenterology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.

ORCID-Profile: Xinjue He

Förderung

  • Fundamental Research Funds for the Central Universities
  • Zhejiang Provincial Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Song, X., Jiang, C., Yu, M., Lu, C., & He, X. (2024). CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16622

Vancouver

Song X, Jiang C, Yu M, Lu C, He X. CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16622

BibTeX
@article{Song2024,
  author = {Song, Xin and Jiang, Chensheng and Yu, Mengli and Lu, Chao and He, Xinjue},
  title = {CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16622}
}
Kostenlos starten →